Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 35 Published: May 31, 2022 Report Code: GDGMDHC22095TDB

The Neuropeptide Y Receptor Type 2 pipeline drugs market research report outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects.

NPY2R Pipeline Drugs Market by Key Therapy Areas

The key therapy areas in the NPY2R pipeline drugs market are metabolic disorders and central nervous system.

NPY2R Pipeline Drugs Market, by Therapy Areas

NPY2R Pipeline Drugs Market, by Therapy Areas

For more therapy area insights, download a free report sample

Key Mechanism of Actions in the NPY2R Pipeline Drugs Market

The key mechanism of action of the NPY2R pipeline drugs market is Neuropeptide Y Receptor Type 2 Agonist.

Key Routes of Administration in the NPY2R Pipeline Drugs Market

The key route of administration in the NPY2R pipeline drugs market is topical.

Key Molecule Types in the NPY2R Pipeline Drugs Market

The key molecule types in the NPY2R pipeline drugs market are peptide, fusion protein, gene therapy, and synthetic peptide.

NPY2R Pipeline Drugs Market, by Molecule Types

NPY2R Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the NPY2R Pipeline Drugs Market

The key companies in the NPY2R pipeline drugs market are Gila Therapeutics Inc, Spark Therapeutics Inc, Takeda Pharmaceutical Co Ltd, and XL-protein GmbH.

NPY2R Pipeline Drugs Market, by Companies

NPY2R Pipeline Drugs Market, by Companies

To know more about the companies, download a free report sample

Neuropeptide Y Receptor Type 2 Pipeline Drugs Market Report Overview

Key Therapy Areas Metabolic Disorders and Central Nervous System
Key Mechanism of Actions Neuropeptide Y Receptor Type 2 Agonist
Key Routes of Administration Topical
Key Molecule Types Peptide, Fusion Protein, Gene Therapy, and Synthetic Peptide
Key Companies Gila Therapeutics Inc, Spark Therapeutics Inc, Takeda Pharmaceutical Co Ltd, and XL-protein GmbH

Scope

This report provides:

  • A snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R).
  • Reviews of targeted therapeutics for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) therapeutics and enlists all their major and minor projects.
  • Assessment of Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
  • Summarization of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics.

Reasons to Buy

  • Gain strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R).
  • Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Key Players

Gila Therapeutics Inc
Spark Therapeutics Inc
Takeda Pharmaceutical Co Ltd
XL-protein GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Overview

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Companies Involved in Therapeutics Development

Gila Therapeutics Inc

Spark Therapeutics Inc

Takeda Pharmaceutical Co Ltd

XL-protein GmbH

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Drug Profiles

CG-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GT-002 – Drug Profile

Product Description

Mechanism Of Action

GT-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PYY-1119 – Drug Profile

Product Description

Mechanism Of Action

History of Events

XL-310 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Dormant Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Discontinued Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Product Development Milestones

Featured News & Press Releases

Feb 11, 2022: CombiGene’s CEO gives business development update

Jan 17, 2022: GMP production of CG01 made available for preclinical studies planned to enable first in human study

Dec 16, 2021: CombiGene and Spark Therapeutics plan to expand the clinical development program to include the U.S. as well as Europe

Nov 04, 2021: BioStock: CombiGene are looking for broader opportunities

Oct 22, 2021: CombiGene’s scientific founders talk about the quantum leap that the epilepsy project CG01 is about to take

Jul 28, 2021: Patent approved in the U.S. and Russia for CombiGenes gene therapy candidate CG01

Jul 26, 2021: CombiGene initiates GMP production of CG01 for the first-in-human study

Jun 30, 2021: BioStock: CombiGene announces several milestones for CG01

Jun 28, 2021: CombiGene and Neurochase begin work to optimize the administration of CG01

Jun 23, 2021: GMP plasmids released – Ready to start GMP production of CG01

Mar 04, 2021: BioStock: CombiGene advances preclinically and recruits post-doc

Mar 01, 2021: The material from the first large-scale production of CG01 is now released for use in the final parts of the preclinical program

Feb 09, 2021: Interview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities’ positive response

Feb 03, 2021: Response from the Swedish and UK Pharmaceutical Regulatory Authorities confirms CombiGene’s plan for CG01’s final preclinical studies

Jan 18, 2021: With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Gila Therapeutics Inc, 2022

Pipeline by Spark Therapeutics Inc, 2022

Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Pipeline by XL-protein GmbH, 2022

Dormant Projects, 2022

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

The key therapy areas in the NPY2R pipeline drugs market are metabolic disorders and central nervous system.

The mechanism of action in the NPY2R pipeline drugs market is Neuropeptide Y Receptor Type 2 Agonist.

The route of administration in the NPY2R pipeline drugs market is topical.

The key molecule types in the NPY2R pipeline drugs market are peptide, fusion protein, gene therapy, and synthetic peptide.

The key companies in the NPY2R pipeline drugs market are Gila Therapeutics Inc, Spark Therapeutics Inc, Takeda Pharmaceutical Co Ltd, and XL-protein GmbH.

$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.